Menu Content/Inhalt

Meet with us

BIO-Europe Spring 
Barcelona, Spain
March 8-10, 2010
and
BioMedical Asia & Drug Discovery World Asia
Singapore
March 16-19, 2010

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. We develop our products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

We independently fund the worldwide development of all of our products while providing expertise in preclinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

The sales turnover of our products through our licensees reached $2.6 billion in 2008.

 

News

04-Feb-2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

07-Jan-2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma

13-Oct-2009
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer

04-Feb-2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

07-Jan-2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma

13-Oct-2009
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer

04-Feb-2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

07-Jan-2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma

13-Oct-2009
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer